X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (14) 14
humans (12) 12
clinical neurology (11) 11
brain neoplasms - drug therapy (9) 9
female (9) 9
middle aged (8) 8
adult (7) 7
aged (7) 7
male (7) 7
oncology (7) 7
glioblastoma (6) 6
neurosciences (6) 6
bevacizumab (5) 5
brain neoplasms - pathology (5) 5
dacarbazine - analogs & derivatives (5) 5
glioma - drug therapy (5) 5
gliomas (5) 5
medicine & public health (5) 5
retrospective studies (5) 5
temozolomide (5) 5
treatment outcome (5) 5
angiogenesis inhibitors - therapeutic use (4) 4
cancer (4) 4
dacarbazine - therapeutic use (4) 4
disease-free survival (4) 4
survival (4) 4
therapy (4) 4
animals (3) 3
brain neoplasms - mortality (3) 3
care and treatment (3) 3
chemotherapy (3) 3
disease progression (3) 3
drug therapy (3) 3
glioblastoma multiforme (3) 3
glioma (3) 3
glioma - pathology (3) 3
malignant glioma (3) 3
neoplasm recurrence, local - pathology (3) 3
neurology (3) 3
recurrent glioblastoma (3) 3
research (3) 3
survival analysis (3) 3
young adult (3) 3
analysis (2) 2
antibodies, monoclonal - therapeutic use (2) 2
antibodies, monoclonal, humanized (2) 2
antibodies, monoclonal, humanized - therapeutic use (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic agents - pharmacology (2) 2
antineoplastic agents, alkylating - therapeutic use (2) 2
antineoplastic agents, phytogenic - therapeutic use (2) 2
bevacizumab efficacy (2) 2
biochemistry & molecular biology (2) 2
brain - pathology (2) 2
brain neoplasms - diagnostic imaging (2) 2
brain neoplasms - genetics (2) 2
brain neoplasms - physiopathology (2) 2
brain neoplasms - radiotherapy (2) 2
brain tumors (2) 2
cell line, tumor (2) 2
cell survival - drug effects (2) 2
development and progression (2) 2
differentiation (2) 2
dose-response relationship, drug (2) 2
drug administration schedule (2) 2
genetic aspects (2) 2
glioblastoma - diagnostic imaging (2) 2
glioblastoma - drug therapy (2) 2
glioblastoma - mortality (2) 2
glioblastoma - pathology (2) 2
glioma - physiopathology (2) 2
glioma - radiotherapy (2) 2
glioma-cells (2) 2
glutarates - metabolism (2) 2
growth (2) 2
health aspects (2) 2
high-grade glioma (2) 2
isocitrate dehydrogenase (2) 2
isocitrate dehydrogenase - genetics (2) 2
isocitrate dehydrogenase - metabolism (2) 2
kinase inhibitor (2) 2
medical research (2) 2
mri (2) 2
mutation (2) 2
neoplasm recurrence, local - drug therapy (2) 2
phase-ii (2) 2
plus irinotecan (2) 2
progression (2) 2
quality of life (2) 2
radiation-therapy (2) 2
radiotherapy (2) 2
recurrence (2) 2
single-agent bevacizumab (2) 2
trial (2) 2
tumors (2) 2
vascular endothelial growth factor (2) 2
) (1) 1
19q (1) 1
1p/19q (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 11, pp. 1533 - 1542
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2016, Volume 22, Issue 23, pp. 5765 - 5771
Purpose: Antiangiogenic treatment with bevacizumab, a mAb to the VEGF, is the single most widely used therapeutic agent for patients with recurrent... 
BEVACIZUMAB EFFICACY | THERAPY | ROBUST | ONCOLOGY | SUBTYPES | OPTIMIZATION | REGISTRATION | RADIOTHERAPY | MICROARRAY DATA | PROGRESSION | TEMOZOLOMIDE | Index Medicus | radiomics | glioblastoma | anti-angiogenic treatment | machine learning
Journal Article
Nature Medicine, ISSN 1078-8956, 08/2018, Volume 24, Issue 8, pp. 1192 - 1203
The oncometabolite (R)-2-hydroxyglutarate (R-2-HG) produced by isocitrate dehydrogenase (IDH) mutations promotes gliomagenesis via DNA and histone methylation.... 
GLIOMA-CELLS | MEDICINE, RESEARCH & EXPERIMENTAL | ACTIVATED PROTEIN-KINASE | ACID | DNA METHYLATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | ISOCITRATE DEHYDROGENASE MUTATIONS | CANCER | CELL BIOLOGY | IN-VIVO | DIFFERENTIATION | EXPRESSION | 2-HYDROXYGLUTARATE | Cell Proliferation | Calcium - metabolism | Humans | RNA, Messenger - metabolism | Immunity | Glioma - genetics | Lymphocyte Activation - immunology | Brain Neoplasms - immunology | Adenosine Triphosphate - metabolism | Paracrine Communication | Receptors, Antigen, T-Cell - metabolism | Signal Transduction | Mice, Inbred C57BL | NFATC Transcription Factors - metabolism | RNA, Messenger - genetics | Brain Neoplasms - genetics | Glioma - immunology | Isocitrate Dehydrogenase - genetics | Mutation - genetics | Polyamines - metabolism | Animals | Cell Line, Tumor | Isocitrate Dehydrogenase - metabolism | T-Lymphocytes - immunology | Glutarates - metabolism | Apoptosis | Molecular genetics | Gliomas | Dosage and administration | Genetic aspects | Research | Genetic transcription | T cells | Drug therapy | Immunosuppressive agents | Transcription factors | Calcium | Transcription | Biosynthesis | Lymphocytes T | NF-AT protein | Calcium signalling | Cancer vaccines | Lymphocytes | DNA methylation | Inhibition | Mutation | Methylation | Isocitrate dehydrogenase | Deoxyribonucleic acid--DNA | Tumors | Index Medicus
Journal Article
Journal Article
Neuro-Oncology, ISSN 1522-8517, 11/2016, Volume 18, Issue 11, pp. 1529 - 1537
Journal Article
Journal Article
Journal of Neuro-Oncology, ISSN 0167-594X, 1/2015, Volume 121, Issue 2, pp. 373 - 380
Journal Article
Journal of Neurology, ISSN 0340-5354, 5/2009, Volume 256, Issue 5, pp. 734 - 741
Temozolomide (TMZ) is the standard of care for patients with newly diagnosed glioblastoma (GBM) as well as those with recurrent anaplastic glioma (AG) and GBM.... 
Neurology | Neurosciences | Chemotherapy | Medicine & Public Health | Glioma | Rechallenge | Temozolomide | Dose-intensified regimens | Neuroradiology | PROGNOSTIC-FACTORS | GLIOBLASTOMA-MULTIFORME | PHASE-II | REGIMEN | CLINICAL NEUROLOGY | MALIGNANT GLIOMA | II CLINICAL-TRIALS | THERAPY | 1ST RELAPSE | Dacarbazine - adverse effects | Humans | Middle Aged | Brain Neoplasms - pathology | Brain Neoplasms - physiopathology | Neoplasm Recurrence, Local - drug therapy | Male | Antineoplastic Agents, Alkylating - administration & dosage | Dose-Response Relationship, Drug | Neoplasm Recurrence, Local - pathology | Young Adult | Glioma - pathology | Dacarbazine - analogs & derivatives | Adult | Female | Retrospective Studies | Dacarbazine - administration & dosage | Drug Administration Schedule | Brain - physiopathology | Treatment Outcome | Neoplasm Recurrence, Local - physiopathology | Brain Neoplasms - drug therapy | Disease Progression | Brain - drug effects | Disease-Free Survival | Brain - pathology | Aged | Glioma - physiopathology | Antineoplastic Agents, Alkylating - adverse effects | Drug Resistance, Neoplasm - physiology | Glioma - drug therapy | Cohort Studies | Drug Resistance, Neoplasm - drug effects | Usage | Diagnosis | Research | Drug therapy | Glioblastoma multiforme | Health aspects | Risk factors | Index Medicus
Journal Article
Journal of Neurochemistry, ISSN 0022-3042, 12/2004, Volume 91, Issue 5, pp. 1067 - 1074
The nervous system is frequently the site of symptomatic toxicity of antineoplastic agents. However, there is limited information about the differential... 
multidrug resistance | Akt | neurons | brain‐derived neurotrophic factor | Brain-derived neurotrophic factor | Neurons | Multidrug resistance | GLIOMA-CELLS | INDUCED APOPTOSIS | NEUROTROPHIC FACTOR | BIOCHEMISTRY & MOLECULAR BIOLOGY | RAT ASTROCYTES | PRIMARY CULTURES | D-ASPARTATE RECEPTOR | PROTEIN-SYNTHESIS | NEUROSCIENCES | NERVE GROWTH-FACTOR | P-GLYCOPROTEIN | brain-derived neurotrophic factor | MULTIDRUG-RESISTANCE | Neurons - pathology | Caspase 9 | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Astrocytes - pathology | Dose-Response Relationship, Drug | Proto-Oncogene Proteins c-bcl-2 - metabolism | RNA, Messenger - biosynthesis | Caspases - metabolism | Drug Interactions | Transfection - methods | Reverse Transcriptase Polymerase Chain Reaction - methods | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Caspase 3 | Antineoplastic Agents - pharmacology | Cell Death - drug effects | Neurons - drug effects | Carrier Proteins | Animals, Newborn | Astrocytes - drug effects | Cell Survival - drug effects | Proto-Oncogene Proteins - antagonists & inhibitors | bcl-X Protein | Blotting, Western - methods | Cell Size - drug effects | Cells, Cultured | Oligodeoxyribonucleotides, Antisense - therapeutic use | Rats | Rats, Sprague-Dawley | Necrosis - prevention & control | Cerebellum - pathology | Necrosis - chemically induced | Gene Expression Regulation - drug effects | Proto-Oncogene Proteins c-akt | Brain-Derived Neurotrophic Factor - administration & dosage | Amino Acid Chloromethyl Ketones - administration & dosage | Animals | Analysis of Variance | Glioma | ATP-Binding Cassette, Sub-Family B, Member 1 - genetics | Chemokines, CC - genetics | bcl-Associated Death Protein | Chemokines, CC - metabolism | Index Medicus
Journal Article
Book Review